Shanghai, China – On March 23, ShanghaiMicroPort EP MedTech Co., Ltd. (“MicroPort EP”) obtained the registrationcertificates of Brazil ANVISA for its developed Columbus™ CardiacElectrophysiology Stimulator.
Columbus™ Cardiac ElectrophysiologyStimulator is indicated for imposing one or several electric pulse stimulus incertain moment of cardiac cycle, observing the cardiac feedback to thestimulus, learning the cardiac electrophysiological features, clarifying themechanism of arrhythmia so as to guide clinical diagnosis and treatment for thetachyarrhythmia. The Brazil ANVISA approval means this product will soon enterthe Brazil market and lay a great foundation for MicroPort® EP to furtherexpand the South American market. In the future, MicroPort EP will continue todeeply explore the Brazilian and South American markets to provide the localpatients and doctors with integrated electrophysiological solutions of highquality and accessibility.